c & c painting, inc.

29 prince road
mahopac, new york 10541

NYS Entity Status
ACTIVE

NYS Filing Date
JULY 02, 2013

NYS DOS ID#
4425913

County
PUTNAM

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2013 - C & C PAINTING, INC.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • Long Live Microsoft Paint! It Helped My Blind Grandpa Keep Making Art
    By Ryan Lasko - Wednesday Jul 26, 2017

    After word spread that Microsoft might kill off its beloved Paint program, an outcry of protest convinced the company to reverse course. Here, Ryan Lasko explains why he loves the old-school art software so much.

    “Just use the spray paint can.”

    Read Full Story

    Source: Fast Company
  • Snap stock is tanking again after user growth slows down
    By Christopher Zara - Thursday Aug 10, 2017

    This is not good news for Snap Inc. The parent company of Snapchat saw its shares tumble in after-hours trading today after it reported disappointing user growth in its Q2 2017 earnings. It’s only the second earnings report since Snap went public in March, and hopes for a turnaround are deteriorating. Shares fell to $11.90 after … Continue reading “Snap stock is tanking again after user growth slows down”

    This is not good news for Snap Inc. The parent company of Snapchat saw its shares tumble in after-hours trading today after it reported disappointing user growth in its Q2 2017 earnings. It’s only the second earnings report since Snap went public in March, and hopes for a turnaround are deteriorating. Shares fell to $11.90 after hours, an all-time low. Snap debuted on the NYSE at $17 a share. It fell below that price a month ago and hasn’t recovered. The company reported daily active users growth of 7 million to 173 million total, but analysts were expecting about 8 million new users, CNBC reports. You can check out Snap’s full earnings release here. We’ll have more after the call later today.

    Read Full Story

    Source: Fast Company
  • 'Junk Insurance' vs. 'Junk News' at the NY Times
    Monday Jul 17, 2017

    Why is “choice” in matters of one’s personal health suddenly a bad thing? 

    Source: American Thinker
  • Time Inc Taps Schraft To Head Foundry's Content Sales, 'New Yorker' Hires First Newsletter Director
    Thursday Jul 13, 2017

    In a move to expand its native advertising business, Time Inc. has promoted Chris Schraft to president of content sales and agency development of The Foundry, its branded content studio. 'The NewYorker' has hired Dan Oshinsky as its first director of newsletters.

    Source: Media Post: Social Media & Marketing Daily
  • Nintendo goes full-on nasty with this week's paint colors in 'Splatoon 2'
    By Kellen Beck - Friday Aug 4, 2017

    This week's Splatfest in Splatoon 2 asks players to choose their favorite condiment — ketchup or mayo — and duke it out in paint-flinging battles to see which one reigns supreme. That's all fine and dandy, except for the corresponding paint colors Nintendo is assigning each team.

    Ketchup fans shoot out ketchup-red paint and mayo fans shoot out mayo-white paint. The red paint looks horrifyingly bloody and the off-white paint looks... nasty. In a sexual way.

    Some people already see the paint-shooting mayhem that is Splatoon as a bit sexual, and throwing cream-colored paint into the mix is not doing the supposedly unaware Nintendo game any favors. And seeing opponents explode in a gush of red paint? Disturbing. Read more...

    More about Gaming, Nintendo, Paint, Splatoon, and Splatoon 2

    Source: Mashable!
  • Abbvie’s hep C drug pricing threatens Gilead’s dominance
    By Max Nisen - Tuesday Aug 8, 2017

    Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.

    Source: SFGATE.com: Business and Technology News
c amp c painting inc mahopac ny